Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Pentoxifylline in Plaque psoriasis: NCT07626788 Clinical Landscape Report 2026
16 September 2026
NCT07626788 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
![[68Ga]Ga-NNS309 in HR Positive/HER2 Negative Lobular Carcinoma: NCT07630961 Clinical Landscape Report 2026](https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/Blog_cover_12_7f0c44f64f.jpg)
9 min read
[68Ga]Ga-NNS309 in HR Positive/HER2 Negative Lobular Carcinoma: NCT07630961 Clinical Landscape Report 2026
16 September 2026
NCT07630961 clinical landscape for HR Positive/HER2 Negative Lobular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Arnovie101 in Evans Syndrome: NCT07629596 Clinical Landscape Report 2026
16 September 2026
NCT07629596 clinical landscape for Evans Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RN-9101 (Jiangsu Provincial People's Hospital) in Relapse multiple myeloma: NCT07628595 Clinical Landscape Report 2026
16 September 2026
NCT07628595 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sitagliptin Phosphate in Uveal Melanoma: NCT07634380 Clinical Landscape Report 2026
16 September 2026
NCT07634380 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tumor infiltrating lymphocytes(NCI) in Melanoma, Cutaneous Malignant: NCT07628894 Clinical Landscape Report 2026
16 September 2026
NCT07628894 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tocilizumab in Lupus Nephritis: NCT07629583 Clinical Landscape Report 2026
16 September 2026
NCT07629583 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Axatilimab-csfr in High grade B-cell lymphoma: NCT07638982 Clinical Landscape Report 2026
16 September 2026
NCT07638982 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT07635485 Clinical Landscape Report 2026
16 September 2026
NCT07635485 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells) (Adjuvant)(Yikang ) in Retinoblastoma: NCT07633756 Clinical Landscape Report 2026
16 September 2026
NCT07633756 clinical landscape for Retinoblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma Multiforme: NCT07635173 Clinical Landscape Report 2026
16 September 2026
NCT07635173 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Probiotic(Mendes) in Uterine Cervical Cancer: CTRI/2026/06/112392 Clinical Landscape Report 2026
16 September 2026
CTRI/2026/06/112392 clinical landscape for Uterine Cervical Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.